Parathyroid hormone and the cardiovascular system

Current Osteoporosis Reports

Volumn 6, Issue 2, 2008, Pages 77-83

  Fitzpatrick, Lorraine A ^a   Bilezikian, John P ^b   Silverberg, Shonni J ^b  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; HEART LEFT VENTRICLE FUNCTION; HORMONE ACTION; HUMAN; HYPERTENSION; MORTALITY; PRIMARY HYPERPARATHYROIDISM; REVIEW; ANIMAL; CARDIOVASCULAR DISEASE; DISEASE MODEL; HYPERPARATHYROIDISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; HYPERPARATHYROIDISM; HYPERTENSION; PARATHYROID HORMONE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 58149136434     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0014-8     Document Type: Review

References (57)

1. Ljunghall S, Abela C, Frank H, et al.: Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 1997, 82:106-112.
2. Hedback GM, Oden AS: The influence of surgery on the risk of death in patients with hyperparathyroidism. World J Surg 1998, 15:399-405.
3. Palmer M, Adami HO, Bergstrom R, Akerstrom G: Mortality after surgery for primary hyperparathyroidism: A follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987, 102:1-7.
4. Wermers RA, Khosla S, Atkinson EJ, et al.: Survival after the diagnosis of hyperparathyroidism: A population-based study. Am J Med 1998, 104:115-122.
5. Vestergaard H, Ostergaard Kristensen L: Normocalcemia and persistent elevated serum concentrations of 1-84 parathyroid hormone after operation for sporadic parathyroid adenoma: Evidence of increased morbidity from cardiovascular disease. World J Surg 2002, 26:657-660.
6. Ogard CG, Engholm MS, Almdal TP, Vestergaard H: Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977-1993 in Denmark. World J Surg 2004, 28:108-111.
7. Kamycheva E, Sundsfjord J, Jorde R: Serum parathyroid hormone levels predict coronary heart disease: The Tromsø Study. Eur J Cardiovasc Prev Rehabil 2004, 11:69-74.
8. Lind L, SAarfors E, Berglund L, et al.: Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 1997, 50:967-973.
9. Jorde R, Sundsfjord J, Fitzgerald P, Bonaa KH: Serum calcium and cardiovascular risk factors and diseases: The Tromsø study. Hypertension 1999, 34:484-490.
10. Leifsson BG, Ahren B: Serum calcium and survival in a large health-screening program. J Clin Endocrinol Metab 1996, 81:2149-2153.
11. Rubin MR, Rundek T, McMahon DJ, et al.: Carotid artery plaque thickness is associated with increased serum calcium levels: The Northern Manhattan study. Atherosclerosis 2007, 194:426-432.
12. Barletta G, De Feo ML, Del Bene R, et al.: Cardiovascular effects of parathyroid hormone: A study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85:1815-1821.
13. Snijder MB, Lips P, Seidell JC, et al.: Vitamin D status and parathyroid hormone levels in relation to blood pressure: A population-based study in older men and women. J Intern Med 2007, 261:558-565.
14. Jorde R, Sundsfjord J, Haug E, Bønaa KH: Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension 2000, 35:1154-1159.
15. Morfis L, Smerdely P, Howes LG: Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 1997, 15:1271-1276.
16. Hulter HN, Melby JC, Peterson JC, Cooke CR: Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1998, 2:360-370.
17. Fliser D, Franek E, Fode P, et al.: Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997, 12:933-938.
18. Nilsson IL, Aberg J, Rastad J, Lind L: Maintained normalization of cardiovascular dysfunction 5 years after parathyroidectomy in primary hyperparathyroidism. Surgery 2005, 137:632-638.
19. Schleiffer R: Parathyroid hormone and genetic hypertension. Int J Cardiol 1992, 35:303-310.
20. Sancho JJ, Rouco J, Riera-Vidal R, Sitges-Serra A: Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992, 16:732-735.
21. Nilsson IL, Rastad J, Johansson K, Lind L: Endothelial vasodilatatory function and blood pressure response to local and systemic hypercalcemia. Surgery 2001, 130:986-990.
22. Gennari C, Nami R, Gonnelli S: Hypertension and primary hyperparathyroidism: Role of the adrenergic and plasma renin angiotensin systems. Miner Electrolyte Metab 1995, 21:77-81.
23. Lakatos P, Tatra A, Foldes J, et al.: Endothelin concentrations are elevated in plasma of patients with primary and secondary hyperparathyroidism. Calcif Tissue Int 1996, 58:70-71.
24. Sangal AK, Kevwitch M, Rao DS, Rival J: Hypomagnesemia and hypertension in primary hyperparathyroidism. South Med J 1989, 82:1116-1118.
25. Almqvist EG, Bondeson AG, Bondeson L, et al.: Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002, 132:1126-1132.
26. Stefenelli T, Abela C, Frank H, et al.: Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 1997, 82:106-112.
27. Piovesan A, Molineri N, Casasso F, et al.: Left ventricular hypertrophy in primary hyperparathyroidism: Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999, 50:321-328.
28. Nilsson IL, Aberg J, Rastad J, Lind L: Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism - effects of parathyroidectomy. Surgery 2000, 128:895-902.
29. Ogard CG, Sondergaard SB, Vestergaard H, et al.: Myocardial perfusion defects and the left ventricular ejection fraction disclosed scintigraphy in patients with primary hyperparathyroidism. World J Surg 2005, 29:914-916.
30. Baykan M, Erem C, Erdogan T, et al.: Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int J Cardiovasc Imaging 2007, 23:323-328.
31. Kosch M, Hausberg M, Vormbrock K, et al.: Impaired flow-mediated vasodilatation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 2000, 47:813-818.
32. Dipette DJ, Christenson W, Nickols MA, Nickols GA: Cardiovascular responsiveness to parathyroid hormone (PTH) and PTH-related protein in genetic hypertension. Endocrinology 1992, 130:2045-2051.
33. Schluter KD, Piper HM: Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Circ Res 1998, 37:34-41.
34. Bogin E, Massry SG, Harary I: Effects of parathyroid hormone on rat heart cell. J Clin Invest 1981, 67:1215-1227.
35. Roca-Cusachs A, Dipette DJ, Nickols G: Regional and systemic hemodynamic effects of parathyroid hormone-related protein: Preservation of cardiac function and coronary and renal flow with reduced blood pressure. J Pharmacol Exp Ther 1991, 256:110-118.
36. Tenner TE Jr, Ramanadham S, Yang MC, Pang PK: Chronotropic actions of bPTH-(1-34) in the right atrium of the rat. Can J Physiol Pharmacol 1983, 61:1162-1167.
37. Smogorzewski M, Zayed M, Zhang YB, et al.: Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol 1993, 264:H1998-H2006.
38. Hara M, Liu Y, Zhen L, et al.: The positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are due to increases in the current I(f), and the slope of the pacemaker potential. Circulation 1997, 96:3704-3709.
39. Nickols GA, Nana AD, Nickols MA, et al.: Hypotension and cardiac stimulation due to the parathyroid hormone-related protein, humoral hypercalcemia of malignancy factor. Endocrinology 1989, 125:834-841.
40. Hara M, Liu YM, Zhen L, et al.: Positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are associated with increases in the current, I(f), and the slope of the pacemaker potential. Circulation 1997, 96:3704-3709.
41. Shimoyama M, Ogino K, Burkhoff D, et al.: Signal transduction pathways and the chronotropic actions of PTH in isolated rat hearts [abstract P-592]. Presented at the 80th Annual Meeting of the Endocrine Society. New Orleans, LA; June 23-27, 1998.
42. Shimoyama M, Ogino K, Taniguchi S, et al.: Signal transduction pathways and chronotropic actions of PTH and its fragments in isolated, perfused rat hearts. Bone 1998, 23(Suppl 5):T197.
43. Ogino K, Burkhoff D, Bilezikian JP: The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 1995, 136:3024-3030.
44. Smith JC, Page MM, John R, et al.: Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85:3515-3519.
45. Rubin MR, Maurer MS, McMahon DJ, et al.: Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrin Metabol 2005, 90:3326-3330.
46. Nilsson IL, Aberg J, Rastad J, Lind L: Circadian cardiac autonomic nerve dysfunction in primary hyperparathyroidism improves after parathyroidectomy. Surgery 2003, 134:1013-1019.
47. Nuzzo V, Tauchmanova L, Fonderico F, et al.: Increased intima-media thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol 2002, 147:453-459.
48. Fallo F, Cella G, Casonato A, et al.: Biochemical markers of endothelial activation in primary hyperparathyroidism. Horm Metab Res 2006, 38:125-129.
49. Rashid G, Bernheim J, Green J, et al.: Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol Dial Transplant 2007, 22:2831-2837.
50. Nyby MD, Hino T, Berger ME, et al.: Desensitization of vascular tissue to parathyroid hormone and parathyroid hormone-related protein. Endocrinology 1995, 136:2497-2504.
51. Chadwick DR, Harrison BJ, Chan P, et al.: Vasoactive and proliferative effects of parathyroid hormone and parathyroid hormone-related peptide on human vascular smooth muscle. Br J Surg 2000, 87:1529-1533.
52. Somjen D, Weisman Y, Kohen F, et al.: 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005, 111:1666-1671.
53. Perkovic V, Hewitson TD, Kelynack KJ, et al.: Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 2003, 26:27-33.
54. Whitfield JF: Osteogenic PTHs and vascular ossification - is there a danger for osteoporotics? J Cell Biochem 2005, 95:437-444.
55. Jono S, Nishizawa Y, Shioi A, et al.: Parathyroid hormone-related peptide as a local regulator of vascular calcification. Arterioscler Thromb Vasc Biol 1997, 17:1135-1142.
56. Ogard CG, Engelmann MD, Kistorps C, et al.: Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol 2005, 63:493-498.
57. Delfini E, Petramala L, Caliumi C, et al.: Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 2007, 56:30-36.